Resources & Guides

Retatrutide is not FDA-approved. It's currently in Phase 3 clinical trials (TRIUMPH program) with expected approval in 2027. Here's everything you need to know about its regulatory status, trial progress, and how to access it today.

Retatrutide is an investigational triple-agonist medication that activates GLP-1, GIP, and glucagon receptors. Phase 2 trials showed 24.2% weight loss, the highest ever recorded for a GLP-1 class drug. Learn everything about this breakthrough medication.

Retatrutide is not approved in any country as of June 2026. It remains investigational, in Phase 3 TRIUMPH trials. Here is the regulatory status across the FDA, EMA, MHRA, TGA, and Health Canada, and what approved versus available actually means.

Retatrutide research peptide vendors operate with no quality standard and no FDA oversight. This guide explains the practical evaluation workflow: which signals to check first, what red flags look like in practice, and how the 2025-2026 FDA enforcement wave changed the vendor landscape.

A current read on the retatrutide FDA timeline. The molecule is still investigational, Lilly plans to submit a Biologics License Application (BLA) in Q1 2027, and the most defensible approval window is late 2027 to 2028. Here is what TRIUMPH Phase 3 has reported, what happens next, and how the timeline compares with tirzepatide.

Unlike semaglutide and tirzepatide, compounded retatrutide is explicitly prohibited under federal law — there is no approved version, so the shortage exemption never applied. This guide explains the legal reality, what's actually in research-peptide vials, and what your real options are.